Get the Stockscreener App
9.39
9.19%
0.79
After Hours:
9.35
-0.04
-0.43%
Corbus Pharmaceuticals Holdings Inc stock is traded at $9.39, with a volume of 334.34K.
It is up +9.19% in the last 24 hours and up +9.57% over the past month.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
See More
Previous Close:
$8.60
Open:
$8.78
24h Volume:
334.34K
Relative Volume:
1.80
Market Cap:
$166.55M
Revenue:
$1.54M
Net Income/Loss:
$-78.54M
P/E Ratio:
-1.5708
EPS:
-5.978
Net Cash Flow:
$-64.50M
1W Performance:
+14.79%
1M Performance:
+9.57%
6M Performance:
-25.77%
1Y Performance:
+76.84%
1-Day Range:
$8.78
$9.715
1-Week Range:
$8.10
$9.715
52-Week Range:
$4.64
$20.56
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Name
Corbus Pharmaceuticals Holdings Inc
Sector
Industry
Phone
617-963-0103
Address
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
9.39 | 152.53M | 1.54M | -78.54M | -64.50M | -5.978 |
VRTX
Vertex Pharmaceuticals Inc
|
446.54 | 112.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
772.64 | 79.21B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
730.25 | 43.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.87 | 41.92B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.52 | 33.05B | 606.42M | -1.28B | -997.58M | -6.403 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | B. Riley Securities | Buy |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Initiated | Wedbush | Outperform |
| Jul-22-24 | Resumed | H.C. Wainwright | Buy |
| Jun-26-24 | Initiated | B. Riley Securities | Buy |
| Jun-03-24 | Reiterated | Oppenheimer | Outperform |
| May-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Mar-06-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-08-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-08-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-08-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-08-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-07-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Mar-26-20 | Initiated | Nomura | Buy |
| Apr-05-19 | Initiated | Jefferies | Buy |
| Mar-20-19 | Initiated | Oppenheimer | Outperform |
| Jan-11-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-26-18 | Initiated | H.C. Wainwright | Buy |
| Dec-07-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-18 | Initiated | B. Riley FBR | Buy |
| Jan-19-18 | Initiated | Raymond James | Outperform |
| Dec-14-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-08-17 | Reiterated | Noble Financial | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Mar-30-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-11-16 | Reiterated | Noble Financial | Buy |
View All
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Latest News
CEO Change: What is the cash position of Corbus Pharmaceuticals Holdings Inc2026 Opening Moves & High Accuracy Buy Signal Tips - baoquankhu1.vn
Published on: 2026-03-31 10:02:36 - baoquankhu1.vn
Aug Shorts: Can Corbus Pharmaceuticals Holdings Inc ride the EV waveWeekly Trend Summary & Daily Technical Forecast Reports - baoquankhu1.vn
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
STU:3371 PB Ratio: 1.04 — 73% Below Median - GuruFocus
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
CRBP SEC FilingsCorbus Pharmaceu 10-K, 10-Q, 8-K Forms - Stock Titan
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Corbus Pharmaceuticals (NASDAQ: CRBP) files $300M shelf to sell equity, debt - Stock Titan
Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Crosses Above 50-Day Moving AverageTime to Sell? - marketbeat.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Repeat Insider Selling Not A Positive Indicator - simplywall.st
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings, Inc. to present CRB-913 oral CB1 inverse agonist at BMO Summit - Traders Union
[EFFECT] Corbus Pharmaceuticals Holdings, Inc. SEC Filing - Stock Titan
How (CRBP) Movements Inform Risk Allocation Models - Stock Traders Daily
If You Invested $1,000 in Corbus Pharmaceu (CRBP) - Stock Titan
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit - Sahm
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Obesity drug from Corbus shows rapid weight loss in early trial - Stock Titan
Corbus Pharmaceuticals Holdings Inc. stock rises Monday, still underperforms market - MarketWatch
Prosight Management LP Decreases Stock Position in Corbus Pharmaceuticals Holdings, Inc. $CRBP - MarketBeat
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Dermatomyositis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Octapharma, Argenx, AstraZeneca, Bristol-Myers Squibb Company, Pfizer Inc., Octapharma AG, Corbus Pharma, Holdings - Barchart
Dermatomyositis Market: Strong Pharma Growth Forecast Through - openpr.com
HC Wainwright Issues Negative Forecast for CRBP Earnings - MarketBeat
Trading Systems Reacting to (CRBP) Volatility - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Medpace Holdings (MEDP), Revolution Medicines (RVMD) and Corbus Pharmaceuticals (CRBP) - The Globe and Mail
Corbus Pharmaceuticals (NASDAQ: CRBP) files $300M shelf registration - Stock Titan
How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33% - Yahoo Finance
Research Analysts Offer Predictions for CRBP FY2030 Earnings - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price Expected to Rise, Oppenheimer Analyst Says - MarketBeat
Oppenheimer Raises Price Target for Corbus Pharmaceuticals (CRBP) to $57 | CRBP Stock News - GuruFocus
Corbus Pharmaceuticals Holdings, Inc. 2024 Annual Report: Pipeline, Intellectual Property, Regulatory Overview, and Business Strategy - Minichart
Corbus Pharmaceuticals (CRBP) Beats Q4 EPS Estimates - GuruFocus
Corbus Pharmaceuticals (NASDAQ: CRBP) details 2025 losses, cash and key trial data - Stock Titan
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results, Highlights Promising CRB-701 and CRB-913 Clinical Updates and Extends Cash Runway Into 2028 - Minichart
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Q4 and annual financial update released, Corbus Pharmaceuticals Holdings, Inc. outlines - Traders Union
Corbus Pharmaceuticals 2025 Financials: Q4 Loss of $20.6M, Beats EstimatesNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Corbus Pharmaceuticals Highlights 2025 Results and Pipeline Progress - TipRanks
Corbus Pharmaceuticals: Fourth Quarter Financial Results Overview - Bitget
Corbus Pharmaceuticals (NASDAQ:CRBP) Releases Quarterly Earnings Results - MarketBeat
Corbus Pharmaceuticals (CRBP) Eyes Breakthroughs with CRB-701 an - gurufocus.com
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update - Bitget
CORBUS PHARMACEUTICALS HLDGS ($CRBP) Releases Q4 2025 Earnings - Quiver Quantitative
Corbus Pharmaceuticals: Q4 Earnings Snapshot - marketscreener.com
Corbus Pharmaceuticals Q4 Earnings Summary & Key Takeaways - Benzinga
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):